JP2019515927A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515927A5
JP2019515927A5 JP2018556356A JP2018556356A JP2019515927A5 JP 2019515927 A5 JP2019515927 A5 JP 2019515927A5 JP 2018556356 A JP2018556356 A JP 2018556356A JP 2018556356 A JP2018556356 A JP 2018556356A JP 2019515927 A5 JP2019515927 A5 JP 2019515927A5
Authority
JP
Japan
Prior art keywords
infection
pharmaceutical composition
composition according
subject
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030236 external-priority patent/WO2017190070A1/en
Publication of JP2019515927A publication Critical patent/JP2019515927A/ja
Publication of JP2019515927A5 publication Critical patent/JP2019515927A5/ja
Pending legal-status Critical Current

Links

JP2018556356A 2016-04-29 2017-04-28 感染症の処置のための方法 Pending JP2019515927A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329514P 2016-04-29 2016-04-29
US62/329,514 2016-04-29
US201662400503P 2016-09-27 2016-09-27
US62/400,503 2016-09-27
US201762470419P 2017-03-13 2017-03-13
US62/470,419 2017-03-13
PCT/US2017/030236 WO2017190070A1 (en) 2016-04-29 2017-04-28 Methods for the treatment of infection

Publications (2)

Publication Number Publication Date
JP2019515927A JP2019515927A (ja) 2019-06-13
JP2019515927A5 true JP2019515927A5 (https=) 2020-06-18

Family

ID=60161141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556356A Pending JP2019515927A (ja) 2016-04-29 2017-04-28 感染症の処置のための方法

Country Status (7)

Country Link
US (2) US20190133995A1 (https=)
EP (1) EP3448377A4 (https=)
JP (1) JP2019515927A (https=)
CN (1) CN109715152A (https=)
AU (1) AU2017258765A1 (https=)
CA (1) CA3022391A1 (https=)
WO (1) WO2017190070A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112368023A (zh) * 2018-06-14 2021-02-12 株式会社钟化 包含药物活性成分的制剂
US20230233456A1 (en) * 2021-03-25 2023-07-27 Per Os Biosciences, Llc Compositions and methods for treating coronavirus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US8586767B2 (en) * 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CN1939917A (zh) * 1999-03-22 2007-04-04 免疫力药品有限公司 大麻酯衍生物及其药用
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
WO2009158499A2 (en) * 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
BR112015019180A8 (pt) * 2013-02-12 2018-01-30 Corbus Pharmaceuticals Inc ácidos tetrahidrocanabinol-11-óicos ultrapuros
US20150328198A1 (en) * 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Similar Documents

Publication Publication Date Title
Blanchette et al. Current therapies in treatment and prevention of fracture wound biofilms: why a multifaceted approach is essential for resolving persistent infections
EP2849777B1 (en) Seaprose for removing bacterial biofilm
US20140371179A1 (en) Methods and Compositions for Treating Esophageal Diseases
JP2020524689A5 (https=)
UA124661C2 (uk) Композиція, що містить антибіотик та диспергатор або антиадгезивний агент
WO2001005400A1 (en) Nitroimidazole external preparations for dermatosis
US11278590B2 (en) Compositions and methods for treating nail infections
AU2020232773B2 (en) Percutaneous anti-microbiota formulations
JP7418475B2 (ja) バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用
JP2019515927A5 (https=)
EP2440216A1 (en) Use of a composition for the treatment of mucositis
US20200323808A1 (en) Wound treatments and compositions
EP3148555A1 (en) Gold (i)-phosphine compounds as anti-bacterial agents
US20250090527A1 (en) Wound treatments and compounds
US20140348787A1 (en) Methods and Compositions for Treating Ear Infections
KR102893477B1 (ko) 당뇨병성 족부 감염의 치료제
WO2021202990A2 (en) Methods for the treatment of betacoronavirus infections
US9763934B2 (en) Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
AU2017258765A1 (en) Methods for the treatment of infection
US20250108027A1 (en) Topical delivery of edta compositions
WO2009043134A1 (en) Mouthwash and method of using same for the treatment of mucositis or stomatitis
高気圧酸素療法で治療した犬の難治性創傷 A non-healing wound in a dog treated with hyperbaric oxygen therapy
US20240100004A9 (en) Topical compositions and methods of formulating same
Frank et al. Physical Incompatibility of Antibiotics and Antimycotics in Infusion Solutions
EP1767199A2 (en) Methods and compositions for treatment of cancer pain